If you typed CMAX Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what CMAX Clinical Research publishes (www.cmax.com.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What CMAX Clinical Research publishes
CMAX Clinical Research is an independent Phase I–II unit in Adelaide, established in 1993, operating a 78-bed purpose-built facility on North Terrace opposite the Royal Adelaide Hospital. Its copy covers pharmaceutical, biotechnology and device companies. CMAX has published as a success story the first-ever human trial of Nacuity's NPI-001, run by its PI in 2017.
CMAX Clinical Research vs bioaccess®
| Dimension | CMAX Clinical Research | bioaccess® |
|---|---|---|
| Core focus | Drug Phase I–II unit with unit-compatible device work | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need first-in-human for a drug or a simple device that needs confinement in a Phase I unit, CMAX is a credible choice.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CMAX Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not CMAX Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the CMAX Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply